{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:33:13Z","timestamp":1774791193990,"version":"3.50.1"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[1992,8]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Polyethylene glycol, covalently linked to superoxide dismutase (PEG-SOD), has a long plasma half-life (greater than 30 hours) and has been proposed as an effective agent for reducing free radical-mediated injury ischemia and reperfusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS AND RESULTS<\/jats:title>\n            <jats:p>Using an isolated rabbit heart perfused with arterial blood from a support rabbit, we have demonstrated that pretreatment with PEG-SOD (30,000 units\/kg, intravenous bolus, 12-24 hours before 60 minutes of normothermic global ischemia), combined with addition of PEG-SOD to the blood perfusion circuit (30,000 units\/kg to the support rabbit) and inclusion of PEG-SOD (150 micrograms\/ml) in a cardioplegic solution, enhanced the postischemic recovery of left ventricular developed pressure (LVDP) from 51 +\/- 6 to 74 +\/- 9 mm Hg (p less than 0.05; n = 9 per group). In further studies we showed that, whereas maximum protection was obtained when PEG-SOD was given as a combined pretreatment and additive to both the cardioplegic and the reperfusate solutions (postischemic LVDP recovery increased from 44 +\/- 4% in the control group to 70 +\/- 3% in the PEG-SOD group), the administration of PEG-SOD during pretreatment plus cardioplegia or during reperfusion alone also resulted in a significant improvement in postischemic function (62 +\/- 7% and 60 +\/- 3%, respectively). However, the use of PEG-SOD as a cardioplegic additive alone failed to afford protection (47 +\/- 4% recovery of LVDP). In dose-response studies (with 0, 3,000, 6,000, 12,000, 30,000, or 60,000 units\/kg; n = 8 per group), maximum recovery of LVDP was obtained with the administration of 12,000 units\/kg of PEG-SOD. Studies of the plasma activity of PEG-SOD confirmed its long half-life and showed that the treatment with PEG-SOD either 1 hour or 12-24 hours before the study resulted in similar levels of plasma activity. In an attempt to assess any involvement of blood-borne elements in the protection afforded by PEG-SOD, studies were also carried out in the crystalloid-perfused rabbit heart, and no protection was observed. Similarly, no protection was observed at any one of a variety of doses in the crystalloid-perfused rat heart.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS<\/jats:title>\n            <jats:p>PEG-SOD can afford protection in the blood-perfused rabbit heart; this protection is dose dependent and probably involves some action of PEG-SOD on blood-borne elements, possibly leukocytes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/01.cir.86.2.672","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:01:09Z","timestamp":1339459269000},"page":"672-682","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["PEG-SOD and myocardial protection. Studies in the blood- and crystalloid-perfused rabbit and rat hearts."],"prefix":"10.1161","volume":"86","author":[{"given":"M","family":"Gali\u00f1anes","sequence":"first","affiliation":[{"name":"Cardiovascular Research, Rayne Institute, St. Thomas' Hospital, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Qiu","sequence":"additional","affiliation":[{"name":"Cardiovascular Research, Rayne Institute, St. Thomas' Hospital, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ezrin","sequence":"additional","affiliation":[{"name":"Cardiovascular Research, Rayne Institute, St. Thomas' Hospital, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D J","family":"Hearse","sequence":"additional","affiliation":[{"name":"Cardiovascular Research, Rayne Institute, St. Thomas' Hospital, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/pdf\/10.1161\/01.CIR.86.2.672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T15:46:53Z","timestamp":1715528813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.86.2.672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,8]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,8]]}},"alternative-id":["10.1161\/01.CIR.86.2.672"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.86.2.672","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,8]]},"assertion":[{"value":"1992-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}